Studies of Lymphoma Suppression and DNA Repair

淋巴瘤抑制和 DNA 修复的研究

基本信息

  • 批准号:
    9226101
  • 负责人:
  • 金额:
    $ 4.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2018-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ionizing radiation (IR), produced by certain minerals in the Earth, represents a major environmental health hazard to man because it causes DNA double-strand breaks (DSBs), highly toxic DNA lesions that often result in genome instability and cancer. It is well established that chromosomal translocations at DSBs can promote lymphoma development. However, there still remains a significant gap in the knowledge of regulatory mechanisms of the repair DNA DSBs induced by IR and lymphoma suppression. The BIR repeat containing ubiquitin-conjugating enzyme (BRUCE) is a conserved protein with chimeric ubiquitin-protein conjugase (E2) and ligase (E3) activities that catalyze post-translational modification of proteins by ubiquitin. Until recently, BRUCE has only been shown to be involved in apoptosis inhibition, cytokinesis, and mouse embryogenesis. Recently, our preliminary studies provide the first indication that BRUCE is a suppressor of lymphoma and a regulatory protein in DNA-repair pathways. In particular, we observed that BRUCE mice are susceptible to lymphomas, and that cells with BRUCE inactivated display genomic instabilities and unrepaired DSBs following ionizing radiation. We also observed that BRUCE acts at a step upstream in DNA-repair cascade by regulating the accumulation, at the site of the DSB, of early DNA-damage signaling proteins and downstream repair proteins following IR. Furthermore, BRUCE has strong relevance to human health in that a reduction in the level of BRUCE gene expression is associated with human lymphomas and also correlates with low survival of lymphoma patients. Based on these findings, we hypothesize that BRUCE suppresses chromosomal abnormalities and lymphomagenesis by promoting DNA DSB repair. We propose two aims to test this hypothesis: (1) To determine chromosomal translocations in lymphomas developed in our heterozygous BRUCEWT/C mutant mice, and whether they are resulted from compromised repair of programmed and/or general DSBs in lymphocytes. We will also determine whether reduced levels of BRUCE protein are associated with lymphoma development by analyzing human lymphoma tissue array. (2) To determine the mechanism by which BRUCE regulates access of repair proteins to the sites of DSB and its implication in DSB-repair pathways of homologous recombination (HR) and non-homologous end joining (NHEJ, both classic and alternative). This proposed work is significant because it will be the first indication that BRUCE is a suppressor of lymphoma and a regulatory protein in DNA repair. This work is also innovative because it has never been expected or even speculated that BRUCE, an anti-apoptosis protein, could regulate DNA repair and tumor suppression. It challenges the current ubiquitin paradigm by placing BRUCE upstream of the current ubiquitin regulatory pathway. These results are expected to lay the groundwork for developing novel agents capable of modulating the level and/or the activity of BRUCE for innovative intervention of lymphoma other related diseases resulting from faulty DNA repair.
描述(由申请人提供):地球上某些矿物产生的电离辐射(IR)代表了对人的主要环境健康危害,因为它会导致DNA双链断裂(DSB)(DSB),高毒性的DNA病变通常会导致基因组不稳定性和癌症。众所周知,DSB的染色体易位可以促进淋巴瘤的发育。然而,在IR和淋巴瘤抑制诱导的修复DNA DSB的调节机制方面仍然存在显着差距。含有泛素偶联酶(Bruce)的BIR重复是一种保守的蛋白质,具有嵌合泛素 - 蛋白 - 蛋白结合酶(E2)和连接酶(E3)活性,可通过泛素催化蛋白质的翻译后修饰。直到最近,Bruce仅显示出参与凋亡抑制,细胞因子和小鼠胚胎发生。最近,我们的初步研究提供了第一个迹象,即Bruce是DNA修复途径中淋巴瘤和调节蛋白的抑制剂。特别是,我们观察到,布鲁斯小鼠易受淋巴瘤的影响,并且在电离辐射电离后,带有布鲁斯的细胞灭活了基因组不稳定性和未经修复的DSB。我们还观察到,布鲁斯通过调节DSB部位的积累,对IR后的早期DNA损伤信号蛋白和下游修复蛋白的积累,在DNA修复级联的上游起作用。此外,布鲁斯与人类健康具有很强的相关性,因为布鲁斯基因表达水平的降低与人类淋巴瘤有关,并且与淋巴瘤患者的存活率较低有关。基于这些发现,我们假设布鲁斯通过促进DNA DSB修复来抑制染色体异常和淋巴作用。我们提出了两个旨在检验这一假设的目的:(1)确定在杂合Brucewt/c突变小鼠中开发的淋巴瘤中的染色体易位,以及它们是否是由淋巴细胞中程序化和/或一般DSB的损害修复而导致的。我们还将通过分析人类淋巴瘤组织阵列来确定降低的Bruce蛋白水平是否与淋巴瘤的发育有关。 (2)确定Bruce调节修复蛋白进入DSB部位的机制及其在同源重组(HR)(HR)(HR)和非同源结局(NHEJ)(NHEJ,Classic and Classic and nhej)中的含义。这项提出的工作很重要,因为这将是Bruce是淋巴瘤和DNA修复中调节蛋白的抑制剂的第一个迹象。这项工作也具有创新性,因为它从未被预期甚至猜测,抗凋亡蛋白的布鲁斯可以调节DNA修复和抑制肿瘤。它通过将布鲁斯上游放置当前泛素调节途径的上游来挑战当前的泛素范式。预计这些结果将为开发能够调节布鲁斯对淋巴瘤创新干预的水平和/或活性的新型药物的基础奠定基础,这是由于DNA修复故障导致的其他相关疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHUNYING DU其他文献

CHUNYING DU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHUNYING DU', 18)}}的其他基金

Novel Targeting of Liver Cancer Deficient of DNA Repair
缺乏 DNA 修复的肝癌的新靶向
  • 批准号:
    10006562
  • 财政年份:
    2019
  • 资助金额:
    $ 4.25万
  • 项目类别:
Novel Targeting of Liver Cancer Deficient of DNA Repair
缺乏 DNA 修复的肝癌的新靶向
  • 批准号:
    9808811
  • 财政年份:
    2019
  • 资助金额:
    $ 4.25万
  • 项目类别:
Studies of Lymphoma Suppression and DNA Repair
淋巴瘤抑制和 DNA 修复的研究
  • 批准号:
    8297090
  • 财政年份:
    2012
  • 资助金额:
    $ 4.25万
  • 项目类别:
Studies of Lymphoma Suppression and DNA Repair
淋巴瘤抑制和 DNA 修复的研究
  • 批准号:
    9031726
  • 财政年份:
    2012
  • 资助金额:
    $ 4.25万
  • 项目类别:
Studies of Lymphoma Suppression and DNA Repair
淋巴瘤抑制和 DNA 修复的研究
  • 批准号:
    8460817
  • 财政年份:
    2012
  • 资助金额:
    $ 4.25万
  • 项目类别:
Studies of Lymphoma Suppression and DNA Repair
淋巴瘤抑制和 DNA 修复的研究
  • 批准号:
    9480909
  • 财政年份:
    2012
  • 资助金额:
    $ 4.25万
  • 项目类别:

相似国自然基金

GnRH拮抗剂通过S100P介导细胞自噬与凋亡影响子宫内膜容受性的分子机制
  • 批准号:
    81701513
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
转录因子GCF2通过PI3K/PTEN/Akt/mTOR通路影响肝癌增殖和凋亡的作用机制研究
  • 批准号:
    81560459
  • 批准年份:
    2015
  • 资助金额:
    37.0 万元
  • 项目类别:
    地区科学基金项目
4E-BP1调控翻译起始影响心肌肥厚和心力衰竭的分子机制研究
  • 批准号:
    81470520
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
生长因子受体结合蛋白2及其相关信号影响细胞自噬和凋亡的机理研究
  • 批准号:
    31171329
  • 批准年份:
    2011
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目
HCV NS5A与FKBP38结合对mTOR信号通路及细胞凋亡的影响
  • 批准号:
    30970158
  • 批准年份:
    2009
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Causes and Downstream Effects of 14-3-3 Phosphorylation in Synucleinopathies
突触核蛋白病中 14-3-3 磷酸化的原因和下游影响
  • 批准号:
    10606132
  • 财政年份:
    2024
  • 资助金额:
    $ 4.25万
  • 项目类别:
Role of Frizzled 5 in NK cell development and antiviral host immunity
Frizzled 5 在 NK 细胞发育和抗病毒宿主免疫中的作用
  • 批准号:
    10748776
  • 财政年份:
    2024
  • 资助金额:
    $ 4.25万
  • 项目类别:
The Role of Glycosyl Ceramides in Heart Failure and Recovery
糖基神经酰胺在心力衰竭和恢复中的作用
  • 批准号:
    10644874
  • 财政年份:
    2023
  • 资助金额:
    $ 4.25万
  • 项目类别:
Elucidating the role of DCAF7 on hematopoietic stem cell maintenance
阐明 DCAF7 对造血干细胞维持的作用
  • 批准号:
    10785443
  • 财政年份:
    2023
  • 资助金额:
    $ 4.25万
  • 项目类别:
Tau protein proteolysis signaling in Alzheimer's disease
阿尔茨海默病中的 Tau 蛋白水解信号
  • 批准号:
    10728202
  • 财政年份:
    2023
  • 资助金额:
    $ 4.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了